Logo image of GANX

GAIN THERAPEUTICS INC (GANX) Stock Price, Quote, News and Overview

NASDAQ:GANX - Nasdaq - US36269B1052 - Common Stock - Currency: USD

1.94  -0.08 (-4.2%)

GANX Quote, Performance and Key Statistics

GAIN THERAPEUTICS INC

NASDAQ:GANX (5/9/2025, 8:00:01 PM)

1.94

-0.08 (-4.2%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3.19
52 Week Low0.89
Market Cap57.09M
Shares29.43M
Float26.49M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06
IPO03-18 2021-03-18


GANX short term performance overview.The bars show the price performance of GANX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 -20

GANX long term performance overview.The bars show the price performance of GANX in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of GANX is 1.94 USD. In the past month the price increased by 22.78%. In the past year, price decreased by -22.71%.

GAIN THERAPEUTICS INC / GANX Daily stock chart

GANX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.97 326.55B
AMGN AMGEN INC 12.81 142.94B
GILD GILEAD SCIENCES INC 12.52 120.65B
VRTX VERTEX PHARMACEUTICALS INC N/A 109.26B
REGN REGENERON PHARMACEUTICALS 11.91 56.98B
ARGX ARGENX SE - ADR 93.64 33.56B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.67B
ONC BEIGENE LTD-ADR 5.79 25.01B
BNTX BIONTECH SE-ADR N/A 22.30B
NTRA NATERA INC N/A 20.66B
SMMT SUMMIT THERAPEUTICS INC N/A 17.79B
BIIB BIOGEN INC 7.47 17.32B

About GANX

Company Profile

GANX logo image Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. The company is headquartered in Bethesda, Maryland and currently employs 23 full-time employees. The company went IPO on 2021-03-18. The firm is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.

Company Info

GAIN THERAPEUTICS INC

4800 Montgomery Lane, Suite 220

Bethesda MARYLAND 20814 US

CEO: Eric Richman

Employees: 31

GANX Company Website

GANX Investor Relations

Phone: 13015001556

GAIN THERAPEUTICS INC / GANX FAQ

What is the stock price of GAIN THERAPEUTICS INC today?

The current stock price of GANX is 1.94 USD. The price decreased by -4.2% in the last trading session.


What is the ticker symbol for GAIN THERAPEUTICS INC stock?

The exchange symbol of GAIN THERAPEUTICS INC is GANX and it is listed on the Nasdaq exchange.


On which exchange is GANX stock listed?

GANX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for GAIN THERAPEUTICS INC stock?

13 analysts have analysed GANX and the average price target is 8.16 USD. This implies a price increase of 320.62% is expected in the next year compared to the current price of 1.94. Check the GAIN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GAIN THERAPEUTICS INC worth?

GAIN THERAPEUTICS INC (GANX) has a market capitalization of 57.09M USD. This makes GANX a Micro Cap stock.


How many employees does GAIN THERAPEUTICS INC have?

GAIN THERAPEUTICS INC (GANX) currently has 31 employees.


What are the support and resistance levels for GAIN THERAPEUTICS INC (GANX) stock?

GAIN THERAPEUTICS INC (GANX) has a support level at 1.9 and a resistance level at 1.96. Check the full technical report for a detailed analysis of GANX support and resistance levels.


Should I buy GAIN THERAPEUTICS INC (GANX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GAIN THERAPEUTICS INC (GANX) stock pay dividends?

GANX does not pay a dividend.


When does GAIN THERAPEUTICS INC (GANX) report earnings?

GAIN THERAPEUTICS INC (GANX) will report earnings on 2025-08-06.


What is the Price/Earnings (PE) ratio of GAIN THERAPEUTICS INC (GANX)?

GAIN THERAPEUTICS INC (GANX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.92).


What is the Short Interest ratio of GAIN THERAPEUTICS INC (GANX) stock?

The outstanding short interest for GAIN THERAPEUTICS INC (GANX) is 1.06% of its float. Check the ownership tab for more information on the GANX short interest.


GANX Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to GANX. When comparing the yearly performance of all stocks, GANX is a bad performer in the overall market: 81.87% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

GANX Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to GANX. Both the profitability and financial health of GANX have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GANX Financial Highlights

Over the last trailing twelve months GANX reported a non-GAAP Earnings per Share(EPS) of -0.92. The EPS increased by 48.31% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -168.36%
ROE -278.1%
Debt/Equity 0.04
Chartmill High Growth Momentum
EPS Q2Q%69.44%
Sales Q2Q%N/A
EPS 1Y (TTM)48.31%
Revenue 1Y (TTM)-100%

GANX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to GANX. The Buy consensus is the average rating of analysts ratings from 13 analysts.


Ownership
Inst Owners7.64%
Ins Owners5.01%
Short Float %1.06%
Short Ratio1.05
Analysts
Analysts84.62
Price Target8.16 (320.62%)
EPS Next Y12.41%
Revenue Next YearN/A